ICON

Choo joins Menicon

Tuesday, August 23, 2011 12:06 PM

Menicon has named Dr. Jennifer Choo manager of specialty lens clinical affairs for Menicon Holdings B.V. Choo will oversee the company's Rose K business while also handling professional and clinical affairs for the company's growing specialty lens portfolio.

More... »

Lexicon’s phase II LX1032 trial shows positive results

Tuesday, August 16, 2011 02:03 PM

Lexicon Pharmaceuticals has reported positive, top-line proof-of-concept data from its recently completed phase II study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract. It is characterized by severe diarrhea and flushing episodes with long-term consequences including malnutrition, heart disease, and death. Symptoms of carcinoid syndrome have been linked to excess production of serotonin by metastatic tumor cells. Telotristat etiprate is designed to reduce serotonin production.

More... »

Omthera names Lloyd VP regulatory affairs

Monday, August 1, 2011 12:32 PM

Omthera Pharmaceuticals reports that Ramona M. Lloyd has joined the company as vice president regulatory affairs, effective immediately.  In this newly created position, Dr. Lloyd will be responsible for the management of all regulatory activities, including regulatory strategy and interactions with the FDA.

More... »

Lexicon successfully completes phase I LX1033 trial

Friday, July 29, 2011 11:16 AM

Lexicon Pharmaceuticals has successfully completed a phase I clinical trial of LX1033, an orally-delivered small-molecule drug candidate for diarrhea-predominant irritable bowel syndrome (IBS-d).  Lexicon plans to move LX1033 forward into a phase II study in patients with IBS-d.

More... »

Icon acquires Firecrest Clinical, adding portal technology to boost site quality while reducing errors and costs

Monday, July 25, 2011 08:02 AM

As large pharmaceutical companies scrutinize the pack of mid- and top-tier CROs to determine who wins the coveted strategic-partnership agreements, there’s a mad scramble among CROs to differentiate themselves from one another and stand out as efficient, high quality, exciting and deserving.

More... »

ICON acquires Firecrest Clinical to enhance site performance

Thursday, July 14, 2011 01:03 PM

Dublin, Ireland-based global CRO Icon has agreed to acquire Firecrest Clinical, a provider of technology solutions that boost investigator site performance and study management.

More... »

Strategic partnerships: a good deal for CROs, or just a cost-cutting measure by big pharma?

Monday, June 13, 2011 08:01 AM

Strategic partnerships with the top 20 pharma companies are what most sizable CROs dream of these days.

More... »

Pfizer chooses Icon and Parexel as its two strategic outsourcing partners in 5-year deals

Monday, June 6, 2011 10:23 AM

Strategic partnerships with large pharma recently have become the holy grail among CROs. And two have been awarded by Pfizer, the largest drug maker in the world.

More... »

Icon's central labs launches cytometry services

Thursday, May 26, 2011 02:31 PM

The central laboratories arm of Ireland-based global CRO Icon has launched a global cytometry services offering through its facilities in New York, Dublin, Bangalore and Singapore, according to PharmaTimes.

More... »

Pfizer strategically partners with Icon, Parexel

Thursday, May 26, 2011 11:53 AM

Pfizer today doled out two large strategic partnership agreements, which have become the brass ring for which most CROs medium and large are jockeying.

More... »